Living with Coronary Heart Disease (CHD) can bring anxiety and uncertainty, especially when dealing with symptoms like chest pain (angina) or shortness of breath. CHD occurs when the major blood vessels supplying the heart become damaged and narrowed by plaque buildup, a process called atherosclerosis. This limits the essential supply of oxygen-rich blood to the heart muscle, affecting your energy, activity level, and overall comfort.

Treatment is vital to improve heart function, relieve painful symptoms, and, most importantly, prevent life-threatening events like heart attacks. While the underlying plaque cannot be completely removed with medication, drug therapies are highly effective at controlling related risk factors and slowing the disease’s progression. Because the severity of blockages and the presence of other conditions (like high blood pressure or diabetes) vary, treatment plans are always highly customized to the individual’s needs (American Heart Association, 2024).

Overview of treatment options for Coronary Heart Disease

The overall treatment strategy for CHD is aggressive and multi-faceted, aiming to target both the symptoms and the underlying cause of the plaque buildup. The main goals are to relieve angina pain, control cardiovascular risk factors (cholesterol, blood pressure), and minimize the risk of blood clots forming on the plaques.

For all patients, treatment begins with significant lifestyle changes, including dietary modification and increased physical activity. However, medication is the necessary foundation for most patients with established CHD. Drug classes are used long-term to keep the disease stable. Procedures, such as angioplasty (stenting) or bypass surgery, are reserved for cases where blood flow is critically blocked and medication alone cannot manage symptoms or risk.

Medications used for Coronary Heart Disease

Medications for CHD are organized into groups that address specific components of the disease:

  • Cholesterol-Lowering Drugs: Statins are the primary medication class used. Examples include simvastatin and atorvastatin. These are critical not just for lowering LDL (“bad”) cholesterol but also for stabilizing the plaque inside artery walls, reducing the risk of rupture.
  • Antiplatelet Drugs: These drugs reduce the likelihood of harmful blood clots forming. Aspirin is commonly prescribed for most CHD patients. For higher-risk cases, a second agent, such as clopidogrel, may be added temporarily.
  • Blood Pressure-Lowering Drugs: Beta-blockers (e.g., metoprolol) and ACE inhibitors (e.g., lisinopril) are widely used. Beta-blockers help the heart beat slower and with less force. ACE inhibitors relax blood vessels and lower pressure.
  • Angina Relief: Nitrates are used to relieve chest pain. Short-acting nitrates (like nitroglycerin) work quickly to relax arteries when angina strikes. Long-acting nitrates help prevent pain throughout the day.

Studies show that consistent adherence to cholesterol-lowering and blood pressure medications provides the greatest reduction in heart attack and stroke risk over time (National Heart, Lung, and Blood Institute, 2022).

How these medications work

Statins lower cholesterol production and circulation, reducing plaque growth. Crucially, they also stabilize existing plaque through anti-inflammatory effects, preventing rupture and clotting.

Antiplatelet drugs, like Aspirin, prevent blood platelets from sticking together to form clots, a common cause of heart attacks, by inhibiting a specific chemical signal.

Blood pressure medications lessen the heart’s workload. Beta-blockers reduce heart rate and force by blocking adrenaline. ACE inhibitors ease blood flow by preventing the production of vessel-narrowing hormones. Nitrates immediately increase blood flow to the heart muscle by rapidly relaxing and widening blood vessels.

Side effects and safety considerations

CHD medications require close monitoring. Statins can cause muscle aches or liver problems, necessitating periodic blood tests. Antiplatelet drugs increase bleeding risk; patients must report unusual bruising or blood in the stool.

Beta-blockers may cause fatigue, slow heart rate, or cold extremities. ACE inhibitors can cause a dry cough. Nitroglycerin often causes headaches or dizziness from sudden blood pressure drops.

Patients with CHD should immediately call 911 for new or worsening chest pain, crushing chest pressure, or pain radiating to the jaw or arm, as these signal an acute heart attack. Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American Heart Association. https://www.heart.org
  2. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
  3. Mayo Clinic. https://www.mayoclinic.org
  4. MedlinePlus. https://medlineplus.gov

Medications for Coronary Heart Disease

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Coronary Heart Disease.

Found 22 Approved Drugs for Coronary Heart Disease

Atorvastatin

Brand Names
Lipitor, Lotrel, Katerzia, Amlodipine, Benazepril, Amlodipine Besylate, Azor, Caduet, Norliqva, Atorvaliq, Lotensin, Olmesartan Medoxomil, Benicar, Tribenzor, Olmesartan Medoxomil Amlodipine, Norvasc

Atorvastatin

Brand Names
Lipitor, Lotrel, Katerzia, Amlodipine, Benazepril, Amlodipine Besylate, Azor, Caduet, Norliqva, Atorvaliq, Lotensin, Olmesartan Medoxomil, Benicar, Tribenzor, Olmesartan Medoxomil Amlodipine, Norvasc
Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia Atorvastatin calcium is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia.

Asprin

Generic Name
Dipyridamole

Asprin

Generic Name
Dipyridamole
Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and extended-release dipyridamole capsules are a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )

TC99M Sestamibi

Brand Names
99M Sestamibi, Cardiolite

TC99M Sestamibi

Brand Names
99M Sestamibi, Cardiolite
Technetium Tc99m Sestamibi is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions Myocardial Imaging: Technetium Tc99m Sestamibi is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Technetium Tc99m Sestamibi is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Technetium Tc99m Sestamibi is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.

Isosorbide

Brand Names
BiDil, Isordil Titradose

Isosorbide

Brand Names
BiDil, Isordil Titradose
Isosorbide mononitrate tablets, USP are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.

Pravastatin

Generic Name
Pravastatin

Pravastatin

Generic Name
Pravastatin
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI,revascularization, andcardiovascularmortalityin hypercholesterolemicpatientswithout clinicallyevidentCHD.
Showing 1-5 of 22
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances